India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...
More »SEARCH RESULT
Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »How to usher in vaccinnovation in India by MK Bhan
-The Economic Times Vaccines are a true gift of science to humanity. In developing countries, prevention is better than cure. Vaccines have a great track record of safety and efficacy and they are amongst the most cost-effective products, which even the poor have access to due to effective systems of procurement and delivery. India's contribution in the vaccine arena is noteworthy. The primary reason behind the country's vaccine success story is...
More »Useless pharmaceutical studies cause real harm by Carl Elliott
Last month, the Archives of Internal Medicine published a scathing reassessment of a 12-year-old research study of Neurontin, a seizure drug made byPfizer. The study, which had included more than 2,700 subjects and was carried out by Parke-Davis (now part of Pfizer), was notable for how poorly it was conducted. The investigators were inexperienced and untrained, and the design of the study was so flawed it generated few if any...
More »Drugs companies to lower price of vaccines in developing countries by Ben Quinn
Announcement comes ahead of London conference on fundraising for global immunisation programmes A promise to reduce the prices of vaccines in developing countries has been announced by a number of big drug companies, ahead of a conference in London at which political leaders will consider how to raise funds for immunisation. The Global Alliance for Vaccines and Immunisation (Gavi), set up by Microsoft founder Bill Gates, said yesterday that Serum Institute of...
More »